Global Angina Pectoris Drugs Industry trends and growth outlook for 2026–2030

The Business Research Company’s 2026 market reports include new capabilities such as market attractiveness scoring and analysis, total addressable market analysis, company scoring matrix, interactive excel data dashboard, improved supply chain analysis, upcoming startups in the market, and overview of key products, aimed at improving the depth, usability, and strategic value of the insights delivered.

What Market Valuation Is Forecasted For The Angina Pectoris Drugs Market By 2030 Starting From Its 2026 Size?

The angina pectoris drugs market size has experienced robust growth in recent years. It is projected to expand from $12.88 billion in 2025 to $13.63 billion in 2026, demonstrating a compound annual growth rate (CAGR) of 5.8%. The growth observed during the historic period can be attributed to the increasing prevalence of coronary heart disease, rising awareness of angina symptoms, the introduction of beta-blockers, the expansion of hospital infrastructure, and the growing adoption of calcium channel blockers.

The angina pectoris drugs market is anticipated to show substantial growth over the next few years. It is projected to expand to $17.67 billion by 2030, at a compound annual growth rate (CAGR) of 6.7%. This expansion during the forecast period can be attributed to progress in precision medicine, the proliferation of wearable cardiac monitoring devices, increasing demand for combination therapies, heightened investment in research and development for anti-ischemic agents, and the incorporation of telehealth into cardiac care. Prominent trends for the forecast period include personalized angina management strategies, the development of minimally invasive drug delivery systems, the use of fixed-dose combination therapies, an expanding geriatric patient population, and the integration of telemedicine with remote cardiac monitoring.

Download the Free Sample Report to Explore Key Market Insights:

https://www.thebusinessresearchcompany.com/sample.aspx?id=10797&type=smp

What Major Growth Drivers Are Shaping The Outlook Of The Angina Pectoris Drugs Market?

The escalating incidence of cardiovascular diseases is projected to drive the growth of the angina pectoris drug market. Cardiovascular diseases encompass a range of conditions affecting the heart and blood vessels, such as coronary artery disease, high blood pressure, heart failure, and stroke. The rising occurrence of these diseases can be attributed to factors like an aging population, unhealthy lifestyles, and the obesity epidemic. Angina pectoris medications, including nitrates, beta-blockers, and calcium channel blockers, effectively ease chest pain and discomfort stemming from insufficient blood flow to the heart, thereby enhancing patients’ overall quality of life. For instance, in January 2024, the American Heart Association, a US-based non-profit organization, reported that the age-adjusted death rate from cardiovascular disease rose to 233.3 per 100,000 in 2024, marking a 4.0% increase from 224.4 per 100,000 in 2023. Therefore, the increasing prevalence of cardiovascular diseases is a key factor propelling the expansion of the angina pectoris drug market.

Which Segment Categories Define The Angina Pectoris Drugs Market?

The angina pectoris drugs market covered in this report is segmented –

1) By Drugs: Nitrates, Antiplatelet Agents, Beta-adrenergic Blocking Agents, Calcium Channel Blockers, Anti-ischemic Agents, Statins

2) By Indication: Stable Angina, Unstable Angina, Prinzmetal’s Angina

3) By Route of Administration: Oral, Parenteral, Transdermal, Other Route Of Administrations

4) By End User: Hospitals, Homecare, Specialty Clinics, Other End Users

Subsegments:

1) By Nitrates: Short-Acting Nitrates, Long-Acting Nitrates

2) By Antiplatelet Agents: Aspirin, Clopidogrel

3) By Beta-Adrenergic Blocking Agents: Non-Selective Beta Blockers, Selective Beta Blockers

4) By Calcium Channel Blockers: Dihydropyridine Calcium Channel Blockers, Non-dihydropyridine Calcium Channel Blockers

5) By Anti-Ischemic Agents: Ranolazine, Ivabradine

6) By Statins: Atorvastatin, Rosuvastatin

What Major Market Trends Are Driving Changes In The Angina Pectoris Drugs Market?

Key companies active in the angina pectoris drug market are prioritizing the adoption of novel technologies to maintain their standing, exemplified by the U.S. Food and Drug Administration’s approval of Labetalol Hydrochloride Injection for treating angina, which helps in better addressing existing consumer requirements. Nitrostat (Nitroglycerin Sublingual Tablets) has been sanctioned by the United States Food and Drug Administration (FDA) for either the immediate treatment or the acute prevention of angina pectoris. As an illustration, in March 2023, Hikma Pharmaceuticals PLC, a UK-based pharmaceutical firm, introduced Labetalol Hydrochloride Injection, USP, packaged in a prefilled syringe. This particular product has received authorization from the Food and Drug Administration of the United States. In healthcare facilities, the 10 mg/2 mL PFS variant is utilized for managing severe hypertension and decreasing blood pressure.

Who Are The Top Companies Competing In The Angina Pectoris Drugs Market?

Major companies operating in the angina pectoris drugs market are Astellas Pharma Inc., Bayer AG, Novartis AG, AstraZeneca PLC, Bausch Health Companies Inc., Merck & Co Inc., Eli Lilly and Company, Pfizer Inc., Abbott Laboratories, Sun Pharmaceutical Industries Limited, Sanofi SA, Boehringer Ingelheim International GmbH, Bristol-Myers Squibb Company, Johnson & Johnson, AbbVie Inc., Amgen Inc., GlaxoSmithKline plc, Lupin Pharmaceuticals Inc., Merck KGaA, Takeda Pharmaceutical Company Limited, Teva Pharmaceutical Industries Ltd., UCB S.A., Servier Laboratories, Otsuka Pharmaceutical Co. Ltd., Regeneron Pharmaceuticals Inc., Ipsen S.A., H. Lundbeck A/S

Read the full angina pectoris drugs market report here:

https://www.thebusinessresearchcompany.com/report/angina-pectoris-drugs-global-market-report

Which Regions Are Projected To Dominate The Angina Pectoris Drugs Market In The Coming Years?

North America was the largest region in the angina pectoris drugs market in 2025. Asia-Pacific is expected to be the fastest-growing region in the forecast period. The regions covered in the angina pectoris drugs market report are Asia-Pacific, South East Asia, Western Europe, Eastern Europe, North America, South America, Middle East, Africa.

Request A Tailored Angina Pectoris Drugs Market Research Report For Competitive Advantage:

https://www.thebusinessresearchcompany.com/customise?id=10797&type=smp

Browse Through More Reports Similar to the Global Angina Pectoris Drugs Market 2026, By The Business Research Company

Angina Pectoris Drugs Market Report 2026

https://www.thebusinessresearchcompany.com/report/angina-pectoris-drugs-global-market-report

Angina Pectoris Drugs Market Report 2026

https://www.thebusinessresearchcompany.com/report/angina-pectoris-drugs-global-market-report

Angina Market Report 2026

https://www.thebusinessresearchcompany.com/report/angina-global-market-report

Get in touch with us:

The Business Research Company: https://www.thebusinessresearchcompany.com/

Americas +1 310-496-7795